Edition:
United Kingdom

People: Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

231.88USD
20 Jul 2018
Change (% chg)

$-0.66 (-0.28%)
Prev Close
$232.54
Open
$232.54
Day's High
$234.91
Day's Low
$231.54
Volume
85,092
Avg. Vol
107,133
52-wk High
$235.04
52-wk Low
$119.43

Patel, Sunil 

Mr. Sunil Patel is Independent Director of the Company. He has more than 20 years of senior management and R&D experience in the biotechnology industry and is currently Chief Financial Officer, Senior Vice President Corporate Development & Finance for OncoMed Pharmaceuticals, a development-stage company focused on therapeutics targeting cancer stem cells. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Allos Therapeutics, Connetics, Abgenix and Gilead Sciences. Mr. Patel also worked at McKinsey & Company serving biotech and pharmaceutical clients and has held scientific research positions at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master’s degree in Molecular Bioengineering/Biotechnology at the University of Washington.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 74,205
Long-Term Incentive Plans, USD --
All Other, USD 195,701
Fiscal Year Total, USD 269,906

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Kozarich

296,271

Matthew Foehr

2,841,260

John Higgins

5,352,640

Matthew Korenberg

1,966,840

Charles Berkman

1,300,170

Nancy Gray

--
As Of  31 Dec 2016